| Primary |
| Blood Glucose Increased |
100.0% |
|
|
| Secondary |
| Type 2 Diabetes Mellitus |
42.7% |
| Product Used For Unknown Indication |
25.2% |
| Diabetes Mellitus |
12.2% |
| Type 1 Diabetes Mellitus |
10.7% |
| Blood Glucose Increased |
2.3% |
| Gout |
1.5% |
| Depression |
0.8% |
| Device Therapy |
0.8% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Hypertension |
0.8% |
| Myelodysplastic Syndrome |
0.8% |
| Neuropathy Peripheral |
0.8% |
| Plasma Cell Myeloma |
0.8% |
|
| Blood Glucose Increased |
13.5% |
| Hypoglycaemic Unconsciousness |
10.8% |
| Hypoglycaemia |
8.1% |
| Weight Increased |
8.1% |
| Wrong Drug Administered |
8.1% |
| Blood Glucose Decreased |
5.4% |
| Depression |
5.4% |
| Nausea |
5.4% |
| Wrong Technique In Drug Usage Process |
5.4% |
| Blood Glucose Fluctuation |
2.7% |
| Bradycardia |
2.7% |
| Cardiac Arrest |
2.7% |
| Diabetic Ketoacidosis |
2.7% |
| Drug Ineffective |
2.7% |
| Dysgeusia |
2.7% |
| Feeling Hot |
2.7% |
| Glycosylated Haemoglobin Increased |
2.7% |
| Hyperglycaemic Unconsciousness |
2.7% |
| Hyperhidrosis |
2.7% |
| Hypersensitivity |
2.7% |
|
| Concomitant |
| Type 2 Diabetes Mellitus |
34.8% |
| Product Used For Unknown Indication |
16.4% |
| Plasma Cell Myeloma |
7.8% |
| Diabetes Mellitus |
6.8% |
| Nephrogenic Anaemia |
4.8% |
| Hypertension |
3.8% |
| Type 1 Diabetes Mellitus |
3.4% |
| Hepatitis C |
2.7% |
| Prostate Cancer Metastatic |
2.7% |
| B-cell Lymphoma |
2.4% |
| Chronic Myeloid Leukaemia |
2.4% |
| Multiple Sclerosis |
2.0% |
| Depression |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.4% |
| Diabetic Nephropathy |
1.4% |
| Myelodysplastic Syndrome |
1.4% |
| Acute Lymphocytic Leukaemia |
1.0% |
| Gastrointestinal Carcinoma |
1.0% |
| Schizophrenia |
1.0% |
| Tuberous Sclerosis |
1.0% |
|
| Pancreatitis |
12.9% |
| Weight Decreased |
10.9% |
| Nausea |
9.5% |
| Vomiting |
9.5% |
| Blood Glucose Increased |
7.5% |
| Pancreatitis Acute |
6.8% |
| Bladder Cancer |
6.1% |
| Renal Failure |
4.8% |
| Tremor |
4.8% |
| Blood Glucose Decreased |
3.4% |
| Renal Failure Chronic |
3.4% |
| Drug Ineffective |
2.7% |
| Renal Failure Acute |
2.7% |
| Treatment Noncompliance |
2.7% |
| Diabetic Ketoacidosis |
2.0% |
| Disease Progression |
2.0% |
| Pain In Extremity |
2.0% |
| Pleural Effusion |
2.0% |
| Product Quality Issue |
2.0% |
| Pruritus |
2.0% |
|
